Life Sciences Tools and Services

HitGen

HitGen released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 160.54 M, actual EPS CNY 0.1

HitGen to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

HitGen to release FY2025 earnings report on April 29 Pre-Market (BJT), forecast revenue CNY 499.5 M, EPS CNY 0.235

HitGen released FY2025 earnings on February 27 Pre-Market (BJT), actual revenue CNY 525.57 M (forecast CNY 499.5 M), actual EPS CNY 0.28 (forecast CNY 0.235)

HitGen released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 155.78 M, actual EPS CNY 0.0506

HitGen released FY2025 9 Months Earnings on October 29 During-Market BJT, actual revenue CNY 369.79 M, actual EPS CNY 0.2341

HitGen released FY2025 Q3 earnings on October 29 During-Market BJT, actual revenue CNY 142.78 M, actual EPS CNY 0.1135

HitGen to Release FY2025 Q3 Earnings on October 30 During-Market (BJT)

HitGen released FY2025 Q2 earnings on August 27 After-Market (BJT), actual revenue CNY 120.28 M, actual EPS CNY 0.0506

HitGen released FY2025 Semi-Annual earnings on August 27 After-Market BJT, actual revenue CNY 227.01 M, actual EPS CNY 0.12

HitGen FY2025 Semi-Annual Earning Release on August 28, 2025 (BJT)

Chengdu Leading Announces Uncertainty in New Drug Development

Morgan Securities Recommends Buy for Chengdu Pioneer

Chengdu Lead Announces an International Patent Application

Chengdu Lead Announces Its First ESG Report

CDPH Terminates Equity Acquisition of Nanjing Haina Pharmaceutical Technology Co., Ltd.

Major Shareholder of Chengdu Lead Reduced Shares

CDH Pharma's Shareholder Huabo Medical Reduced Shares

MInsheng Securities Releases Buy Rating Report on Chengdu Pioneer

Chengdu Prexium Shares Reduced by Major Shareholder

688222

HitGen Inc. (SSE:released its 2025 Sustainability Report on April 29, 2026. The report outlines the company's ESG philosophies, sustainable practices, and performance. CEO Dr. Jin Li emphasized the importance of integrating sustainable development into strategy and operations. HitGen focuses on optimizing governance, ensuring product safety, and fostering employee and community growth. The company is committed to green development and addressing climate change. HitGen aims to be a world-class biopharmaceutical enterprise, leveraging innovative technologies to enhance human health and quality of life.

prnewswire

07:00 ETESG | HitGen Releases 2025 Sustainability Report

600880

002131

002324

After the holiday, more than 110 individual stocks were researched by institutions, with Entropy Technology having the most research institutions. Entropy Technology had 132 institutions conducting research, including 38 fund companies, 8 securities companies, 21 private equity firms, and 13 insurance companies. Chaojie Co., Ltd. was researched by over 100 institutions. In terms of market performance, the average increase of stocks researched by institutions in the past week was nearly 8%, with stocks such as PRET, HitGen, Leo, and B-RAY MEDIA all rising over 30%. (Securities Times)

36Kr

B-RAY MEDIA

PRET

Post-holiday institutional research stocks exposed

HitGen Inc. partners with BioAge Labs to initiate a Phase 1 clinical study of BGE-102, a novel NLRP3 inhibitor targeting obesity. This milestone triggers a payment to HitGen under their collaboration agreement. BGE-102, developed using HitGen's DEL technology, shows promise in treating age-related inflammation and metabolic disorders. Both companies continue to collaborate on drug discovery programs, leveraging HitGen's advanced screening technology and BioAge's insights into human aging biology.

StockTitan

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor | BIOA Stock News

HitGen's partner BioAgeLabs, Inc. recently launched a Phase I clinical study of the novel NLRP3 inhibitor BGE-102. This compound was obtained through screening of HitGen's DNA-encoded compound library, and HitGen will receive relevant milestone payments according to the cooperation agreement, with specific amounts not disclosed. BGE-102 is an oral small molecule NLRP3 inhibitor with a novel structure and good brain penetration, aimed at treating obesity

Zhitong

HitGen: Partner BioAge launches Phase I clinical study of novel NLRP3 inhibitor BGE-102

688356

603127

06127

688382

003020

A-share innovative drug concept stocks fluctuated lower, with InventisBio falling over 10%. Other stocks such as Huahai Pharmaceutical, JENKEM, Lifeon Pharmaceutical, JOINN, Guangsheng Tang, HitGen, and Baillie Gifford also dropped more than 6%

JENKEM

JOINN

InventisBio

Lifeon Pharmaceutical

688658

688221

002294

603222

Innovative drug concept stocks are repeatedly active, Chimin hit the daily limit, JENKEM rose over 10%, YKYY, Nossan, Frontier Biotechnologies, Salubris, and HitGen followed suit

YKYY

Froniter Biotechnologies

Salubris

Chimin

Innovative drug concept stocks are repeatedly active, Chimin hits the daily limit

688202

603259

02359

688073

688131

A-share innovative drug concept stocks rose again, with Chemexpress, HitGen, and Medicilon increasing by over 10%, while Bide and WuXi AppTec also followed suit

Wallstreetcn

Medicilon

WuXi AppTec

WUXI APPTEC

Bide

Chemexpress

HitGen Inc. has launched OpenDEL™ 5.0, an advanced DNA-encoded library (DEL) technology designed to enhance drug discovery. This new version features 4 billion diverse compounds, including 3.8 billion small molecules and 200 million peptide compounds, offering a 25% increase in library size. OpenDEL™ 5.0 includes 59 distinct libraries and an optional macrocycle library for targeting challenging biological targets. The streamlined workflow and next-day shipping aim to expedite the research process for scientists in both industry and academia.

09:30 ET
			
			
				Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0

002463

300476

SOXL

36Kr learned that the three major A-share indices closed mixed at noon, with the Shanghai Composite Index up 0.12%, the Shenzhen Component Index down 0.13%, and the ChiNext Index down 0.52%; CRO and high-frequency PCB concepts led the decline, with VGT falling over 4%, WuXi AppTec, HitGen, and WUS dropping over 3%; semiconductor and consumer electronics sectors saw the largest gains, with Cambricon rising over 4%, and Foxconn Industrial Internet and Luxshare Precision rising over 3%

Direxion Semicon Bull 3X

The three major A-share indices closed mixed at midday, with the CRO concept leading the decline

HitGen announced on the evening of August 4th that its shareholder Shenzhen JunTian Investment Enterprise intends to reduce its holdings of the company's shares by a total of 2 million shares through centralized bidding, which accounts for approximately 0.5% of the company's total share capital; Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd. intends to reduce its holdings of the company's shares by no more than 3 million shares through centralized bidding, which accounts for approximately 0.75% of the company's total share capital

HitGen: Shareholders plan to reduce their holdings by no more than 5 million shares of the company

HitGen(688222.SH)